Stoke Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
Stoke Therapeutics (Nasdaq: STOK), a biotechnology company focused on RNA medicine to restore protein expression, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference.
The company's Interim Chief Executive Officer Ian F. Smith will deliver a presentation on Tuesday, April 8, 2025, at 8:45 a.m. ET. Stoke's lead investigational medicine, zorevunersen, is being developed as a potential first-in-class disease-modifying treatment for Dravet syndrome.
Investors and interested parties can access the live webcast and archived replay of the presentation through Stoke's website investor section at https://investor.stoketherapeutics.com/.
Stoke Therapeutics (Nasdaq: STOK), un'azienda biotecnologica focalizzata sulla medicina a RNA per ripristinare l'espressione proteica, ha annunciato la sua partecipazione alla 24ª Conferenza Virtuale Annuale di Needham sulla Salute.
Il CEO ad interim dell'azienda, Ian F. Smith, terrà una presentazione martedì 8 aprile 2025, alle 8:45 ET. Il principale medicinale in fase di studio di Stoke, zorevunersen, è in fase di sviluppo come potenziale trattamento modificante la malattia di prima classe per la sindrome di Dravet.
Investitori e parti interessate possono accedere alla diretta e alla registrazione della presentazione attraverso la sezione investitori del sito web di Stoke all'indirizzo https://investor.stoketherapeutics.com/.
Stoke Therapeutics (Nasdaq: STOK), una empresa biotecnológica centrada en la medicina de ARN para restaurar la expresión de proteínas, ha anunciado su participación en la 24ª Conferencia Virtual Anual de Salud de Needham.
El CEO interino de la empresa, Ian F. Smith, realizará una presentación el martes 8 de abril de 2025, a las 8:45 a.m. ET. El principal medicamento en investigación de Stoke, zorevunersen, se está desarrollando como un posible tratamiento modificador de la enfermedad de primera clase para el síndrome de Dravet.
Los inversores y partes interesadas pueden acceder a la transmisión en vivo y a la repetición archivada de la presentación a través de la sección de inversores del sitio web de Stoke en https://investor.stoketherapeutics.com/.
Stoke Therapeutics (Nasdaq: STOK), 단백질 발현을 복원하기 위한 RNA 의약품에 중점을 둔 생명공학 회사가 제24회 니드햄 가상 헬스케어 컨퍼런스에 참여한다고 발표했습니다.
회사의 임시 CEO인 Ian F. Smith는 2025년 4월 8일 화요일 오전 8시 45분 ET에 발표를 진행할 예정입니다. Stoke의 주요 연구 의약품인 zorevunersen은 드라베 증후군에 대한 잠재적인 1세대 질병 수정 치료제로 개발되고 있습니다.
투자자와 이해 관계자는 Stoke 웹사이트의 투자자 섹션(https://investor.stoketherapeutics.com/)을 통해 발표의 실시간 웹캐스트와 아카이브 재생을 이용할 수 있습니다.
Stoke Therapeutics (Nasdaq: STOK), une entreprise de biotechnologie axée sur la médecine à ARN pour restaurer l'expression des protéines, a annoncé sa participation à la 24e Conférence Virtuelle Annuelle de Needham sur la Santé.
Le PDG par intérim de l'entreprise, Ian F. Smith, présentera une communication le mardi 8 avril 2025, à 8h45 ET. Le principal médicament en cours d'investigation de Stoke, zorevunersen, est en cours de développement en tant que traitement modificateur de la maladie de première classe potentiel pour le syndrome de Dravet.
Les investisseurs et les parties intéressées peuvent accéder au webcast en direct et à la rediffusion archivée de la présentation via la section investisseurs du site Web de Stoke à l'adresse https://investor.stoketherapeutics.com/.
Stoke Therapeutics (Nasdaq: STOK), ein biotechnologisches Unternehmen, das sich auf RNA-Medizin zur Wiederherstellung der Proteinexpression konzentriert, hat seine Teilnahme an der 24. jährlichen virtuellen Gesundheitskonferenz von Needham bekannt gegeben.
Der interimistische CEO des Unternehmens, Ian F. Smith, wird am Dienstag, den 8. April 2025, um 8:45 Uhr ET eine Präsentation halten. Das führende Prüfpräparat von Stoke, zorevunersen, wird als potenzielle erstklassige krankheitsmodifizierende Behandlung für das Dravet-Syndrom entwickelt.
Investoren und interessierte Parteien können über den Investorenbereich der Website von Stoke unter https://investor.stoketherapeutics.com/ auf den Live-Stream und die archivierte Wiederholung der Präsentation zugreifen.
- None.
- None.
A live webcast of the presentation, along with an archived replay, will be available in the Investors & News section of Stoke’s website at https://investor.stoketherapeutics.com/.
About Stoke Therapeutics
Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine. Using Stoke’s proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore naturally-occurring protein levels. Stoke’s first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome and is expected to enter Phase 3 development in 2025. Stoke’s initial focus are diseases of the central nervous system and the eye that are caused by a loss of ~
View source version on businesswire.com: https://www.businesswire.com/news/home/20250401009107/en/
Stoke Media & Investor Contacts:
Dawn Kalmar
Chief Communications Officer
dkalmar@stoketherapeutics.com
781-303-8302
Doug Snow
Director, Communications & Investor Relations
IR@stoketherapeutics.com
508-642-6485
Source: Stoke Therapeutics, Inc.
FAQ
When is Stoke Therapeutics (STOK) presenting at the Needham Healthcare Conference 2025?
What is zorevunersen and what condition does STOK aim to treat with it?
How can investors watch Stoke Therapeutics' (STOK) Needham Conference presentation?
Who will represent STOK at the 2025 Needham Healthcare Conference?
